The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1561
Angiotensin II (Giapreza) for Septic Shock
The full article is available to subscribers Subscriber Login   

The FDA has approved Giapreza (La Jolla), an IV formulation of synthetic angiotensin II, to increase blood pressure in adults with septic or other vasodilatory shock, such as anaphylactic or neurogenic shock. Angiotensin is a naturally occurring peptide hormone in the renin-angiotensin-aldosterone system (RAAS). Giapreza is the first synthetic angiotensin II product to become available in the US.

TREATMENT OF SEPTIC SHOCK — Septic shock is the most common form of vasodilatory shock. It is characterized by reduced blood pressure and decreased organ perfusion, which can lead to irreversible organ damage.

Vasopressors are the standard treatment for septic shock when IV fluids alone do not raise blood pressure; recent guidelines recommend use of norepinephrine, a potent alpha1- and beta1-adrenergic agonist, as the initial vasopressor of choice. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Angiotensin II (Giapreza) for Septic Shock
Article code: 1561d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian